http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
반희정,강현욱,김우진,박찬우,오인재,권용수,김규식,김유일,임성철,김영철 대한결핵 및 호흡기학회 2012 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.114 No.-
Backgrounds: Platinum-based doublets are recommended as first-line treatment of stage IV non-small-cell lung cancer (NSCLC). Oxaliplatin is more potent than cisplatin, requiring fewer DNA adducts to provide equivalent cytotoxicity. The objective of this study is to evaluate the efficacy and safety of oxaliplatin combined with docetaxel as a first line treatment of stage IV NSCLC. Methods: This is prospective, single-center, phase II trial. Patients with chemotherapy-naive NSCLC received docetaxel 60 mg/m2 (day 1) and oxaliplatin 70 mg/m2 (day 2) every 3 weeks for up to 6 cycles. The primary endpoint was objective response rate (ORR) and the secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. Treatment response was evaluated according to version 1.1 of Response Evaluation Criteria in Solid Tumors. Results: For this preliminary analysis, 33 patients were enrolled and response evaluation was possible in 31. In response evaluable patients, there were no complete response, 10 partial response, 17 stable disease. ORR was 30.3% and disease control rate was 81.8%. Median PFS was 127 days (95% confidence interval, 59-195) and median OS was 394 days (95% confidence interval, 264-524). Grade 3-4 toxicities occurred in 45% of patients, and the most common hematologic toxicity was neutropenia. There were two cases of hyperglycemia and sepsis. Conclusions: This study suggests that the combination of oxaliplatin and docetaxel is effective in patients with NSCLC, with reasonable toxicities.
Prevalence of Nontuberculous Mycobacterium in Positive Acid-Fast Bacilli Culture
반희정,이보람,유진영,박찬우,김우진,강현욱,권용수,오인재,김규식,김유일,임성철,김영철 대한결핵 및 호흡기학회 2012 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.114 No.-
Objective: To evaluate the prevalence of Mycobaterium Tuberculosis complex and Nontuberculous mycobacterial (NTM) pul-monary infection after using specimen grown in liquid medium. Methods: Patients with positive acid-fast bacilli (AFB) culture from november 2011 to september 2012 at Chonnam National University Hospital were retrospectively reviewed. To identify NTM lung disease, we then reviewed the clinical and radiologic characteristics of the patients from whom NTM was isolated. Results: During the study period, Of a total of 465 patents with 947 positive AFB cultures, 451 NTM isolates were recovered from 258 patients. Patients with NTM isolates were 140 male and mean age were 67 (range 19-93). NTM isolates were Mycobacterium avium complex (n=104, 40.3%) and Mycobacterium abcessus (n=18, 7%). NTM species identification was not performed for 123 NTM isolates. Of these 258 patients, 69 patients (26.7%) were determined to have definite NTM lung disease, 39 patients (15.1%) had respiratory symptoms and chest images without NTM species idendification. Of 69 patients with NTM lung disease were Mycobacterium avium complex (n=56, 81.2%) and Mycobacterium abcessus (n=11, 15.9%). In 69 patients with NTM lung disease, 16 patients (23.2%) manifested the cavitary form, 27 patients (39.1%) exhibited the bronchiectatic form and 26 patients (37.7%) revealed the nodular or consolidative form. Conclusions: About one half of positive AFB culture were NTM isolates. And then one half of patients whom was NTM isolated had clinically significant NTM lung infections.
반희정 ( Hee Jung Ban ),지수영 ( Su Young Chi ),오인재 ( In Jae Oh ),김규식 ( Kyu Sik Kim ),주진영 ( Jin Yung Ju ),권용수 ( Yong Soo Kwon ),김유일 ( Yu Il Kim ) 대한내과학회 2009 대한내과학회지 Vol.77 No.3
A 54-year-old man presented with a cough, sputum, and fever. His chest X-ray showed atelectasis in the right middle lobe. Computed tomography revealed obstruction of the bronchus intermedius by an endobronchial tumor. The first bronchoscopic biopsy specimens suggested lipoma. We resected the tumor via rigid bronchoscopy under general anesthesia and the final pathology report revealed a cartilaginous hamartoma. Subsequently, he has been followed for more than 1 year without recurrence. (Korean J Med 77:349-352, 2009)
재발된 소세포폐암환자에서 이차 약제로 사용되는 Belotecan (CKD-602)의 임상적 효용성
반희정 ( Hee Jung Ban ),오인재 ( In Jae Oh ),김규식 ( Kyu Sik Kim ),주진영 ( Jin Yung Ju ),권용수 ( Yong Soo Kwon ),김유일 ( Yu Il Kim ),임성철 ( Sung Chul Lim ),김영철 ( Young Chul Kim ) 대한결핵 및 호흡기학회 2009 Tuberculosis and Respiratory Diseases Vol.66 No.2
연구배경: Belotecan (Camtobell, CKD-602, Chongkundang Pharm., Korea)은 camptothecin의 치환체로 topoisomerase I 효소를 억제하여 항암효과를 나타내는 것으로 알려져 있다. 이에 2차 항암화학요법에 치료제로써 Belotecan의 효과, 생존율 및 부작용에 대해 연구하였다. 방법: 이에 소세포폐암에서 etoposide와 platinum을 사용한 1차 항암화학요법에서 실패한 49명의 환자들을 대상으로 2차 항암화학요법에 Belotecan을 투약하였다. 결과: 전체 반응률은 25%였으며, 11명의 환자에서 partial response를 보였다. 또한 1차 항암화학요법 이후 90일 이내에 재발한 군과 90일 이상 경과한 군간에 유의한 차이는 보이지 않았다. 전체 환자의 중심생존기간은 10.3개월(290일)이었고, 비반응군에서는 186일(95% CI; 67~305)로 반응군의 471일(95% CI; 234~568)에 비해 생존기간의 감소 유의하게 있음을 확인하였다(p=0.07). 결론: 2차 항암화학요법의 치료제로써 Belotecan의 효능과 부작용에 대해서는 향후 무작위 비교 연구가 필요할 것으로 사료된다. Background: Belotecan (Camtobell, CKD-602, Chong-kundang Pharm., Korea), a camptothecin derivative, has anticancer effects by inhibiting topoisomerase I such as topotecan. This study observed the response, survival and toxicity of belotecan monotherapy after the failure of etoposide and platinum (EP). Methods: Forty nine small cell lung cancer (SCLC) patients (M/F=41/8; age, 64.5±7.6 (mean±SD) years), who failed in their first line chemotherapy were enrolled in this study. Twenty one SCLC patients showed relapsed lung cancer more than 90 days after their prior EP chemotherapy (sensitive relapse group, SR) and 28 patients relapsed within 90 days (refractory relapse group, RR). Results: The response rate was 25%. Eleven patients showed partial responses and 5 patients could not be checked. The response rate of the SR and RR patients was similar. The relative dose intensity was lower in the responders (78±15%) than non-responders (83±13%, p=0.03). The median survival time (MST) was 10.3 months (290 days). The MST of the non-responders and responders was 186 days (95% CI; 67~305) and 401 days (95% CI; 234∼568, p=0.07), respectively. The median progression free survival (MPFS) was similar in the SR (79 days) and RR (67 days) patients. Grade 3~4 neutropenia, anemia, and thrombocytopenia were observed in 59.6%, 12.8% and 23.4% of patients, respectively. Conclusion: The efficacy and survival were demonstrated in the second-line setting. However, a randomized comparative trial with topotecan will be needed.